These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22140576)

  • 1. Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.
    Park JB; Kim BK; Kwon YW; Muller DN; Lee HC; Youn SW; Choi YE; Lee SW; Yang HM; Cho HJ; Park KW; Kim HS
    PLoS One; 2011; 6(11):e28327. PubMed ID: 22140576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas.
    Golledge J; Mangan S; Clancy P
    Stroke; 2007 May; 38(5):1501-8. PubMed ID: 17363721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation.
    Finn AV; John M; Nakazawa G; Polavarapu R; Karmali V; Xu X; Cheng Q; Davis T; Raghunathan C; Acampado E; Ezell T; Lajoie S; Eppihimer M; Kolodgie FD; Virmani R; Gold HK
    Circ Res; 2009 Nov; 105(10):1003-12. PubMed ID: 19797172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.
    Zhang YF; Zou XL; Wu J; Yu XQ; Yang X
    Inflammation; 2015 Dec; 38(6):2105-15. PubMed ID: 26047949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.
    Goetze S; Kintscher U; Kim S; Meehan WP; Kaneshiro K; Collins AR; Fleck E; Hsueh WA; Law RE
    J Cardiovasc Pharmacol; 2001 Dec; 38(6):909-21. PubMed ID: 11707695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitzone suppresses angiotensin II-induced production of KLF5 and cell proliferation in rat vascular smooth muscle cells.
    Gao D; Hao G; Meng Z; Ning N; Yang G; Liu Z; Dong X; Niu X
    PLoS One; 2015; 10(4):e0123724. PubMed ID: 25874449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.
    Hao GH; Niu XL; Gao DF; Wei J; Wang NP
    Br J Pharmacol; 2008 Apr; 153(7):1409-19. PubMed ID: 18278065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of peroxisome proliferator-activated receptor-γ agonists on the generation of microparticles by monocytes/macrophages.
    Neri T; Cordazzo C; Carmazzi Y; Petrini S; Balìa C; Stefanelli F; Amoruso A; Brunelleschi S; Breschi MC; Pedrinelli R; Paggiaro P; Celi A
    Cardiovasc Res; 2012 Jun; 94(3):537-44. PubMed ID: 22425902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of PPAR-γ by pioglitazone attenuates oxidative stress in aging rat cerebral arteries through upregulating UCP2.
    Wang P; Li B; Cai G; Huang M; Jiang L; Pu J; Li L; Wu Q; Zuo L; Wang Q; Zhou P
    J Cardiovasc Pharmacol; 2014 Dec; 64(6):497-506. PubMed ID: 25490415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.
    Ren L; Liu N; Zhi H; Li Y; Li Y; Tang R; Sheng Z
    Cardiovasc Diabetol; 2011 Jan; 10():10. PubMed ID: 21269478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.
    Goetze S; Xi XP; Kawano H; Gotlibowski T; Fleck E; Hsueh WA; Law RE
    J Cardiovasc Pharmacol; 1999 May; 33(5):798-806. PubMed ID: 10226869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.
    Hou X; Zhang Y; Shen YH; Liu T; Song S; Cui L; Bu P
    Eur J Pharmacol; 2013 Sep; 715(1-3):196-203. PubMed ID: 23791613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of proliferator-activated receptor-γ agonist on vascular endothelial injuries in septic rats].
    Wang J; Dai L; Yu L; Sun Y
    Zhonghua Yi Xue Za Zhi; 2015 Apr; 95(15):1179-83. PubMed ID: 26081365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells.
    Wu Y; Zhao XD; Zhuang Z; Xue YJ; Cheng HL; Yin HX; Shi JX
    Brain Res; 2010 Mar; 1322():102-8. PubMed ID: 20132800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.
    Churi SB; Abdel-Aleem OS; Tumber KK; Scuderi-Porter H; Taylor BK
    J Pain; 2008 Jul; 9(7):639-49. PubMed ID: 18387855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.
    Benkirane K; Viel EC; Amiri F; Schiffrin EL
    Hypertension; 2006 Jan; 47(1):102-8. PubMed ID: 16344371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis.
    Gao DF; Niu XL; Hao GH; Peng N; Wei J; Ning N; Wang NP
    Biochem Pharmacol; 2007 Jan; 73(2):185-97. PubMed ID: 17074304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PPAR-Gamma Agonist Rosiglitazone Suppresses Fibrotic Response in Human Pterygium Fibroblasts by Modulating the p38 MAPK Pathway.
    Nuwormegbe SA; Sohn JH; Kim SW
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5217-5226. PubMed ID: 29049722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1.
    Benkirane K; Amiri F; Diep QN; El Mabrouk M; Schiffrin EL
    Am J Physiol Heart Circ Physiol; 2006 Jan; 290(1):H390-7. PubMed ID: 16155101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.